Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options

摘要: Idiopathic recurrent pericarditis affects 30-50% of patients with a previous attack pericarditis. The etiopathogenesis is incompletely understood and most cases remain idiopathic presumed immune-mediated pathogenesis. mainstay therapy aspirin or nonsteroidal anti-inflammatory drug plus colchicine the possible adjunct low-to-moderate dose corticosteroid in more difficult cases. Colchicine as an to reduces by 50% subsequent rate. For true refractory failure standard combination therapies, new emerging options especially include human intravenous immunoglobulins biological agents (i.e., anakinra). outcome good negligible risk developing constrictive Thus, it important reassure on their prognosis, explaining nature disease likely course. Moreover, therapeutic choices should less toxic favor cheaper drugs whenever possible.